Addus HomeCare Corp has a consensus price target of $95.3, established from looking at the 32 latest analyst ratings. The last 3 analyst ratings were released from Barclays, Oppenheimer, and Barclays on April 23, 2024, March 26, 2024, and March 6, 2024. With an average price target of $96.33 between Barclays, Oppenheimer, and Barclays, there's an implied 1.90% upside for Addus HomeCare Corp from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/23/2024 | ADUS | Buy Now | Addus HomeCare | $94.54 | -12.21% | Barclays | Andrew Mok | → $83 | Downgrade | Equal-Weight → Underweight | Get Alert |
03/26/2024 | ADUS | Buy Now | Addus HomeCare | $94.54 | 24.81% | Oppenheimer | Michael Wiederhorn | $118 → $118 | Maintains | Outperform | Get Alert |
03/06/2024 | ADUS | Buy Now | Addus HomeCare | $94.54 | -6.92% | Barclays | Andrew Mok | → $88 | Initiates | → Equal-Weight | Get Alert |
02/29/2024 | ADUS | Buy Now | Addus HomeCare | $94.54 | 7.89% | RBC Capital | Ben Hendrix | → $102 | Reiterates | Outperform → Outperform | Get Alert |
02/05/2024 | ADUS | Buy Now | Addus HomeCare | $94.54 | — | William Blair | Jared Haase | — | Assumes | → Outperform | Get Alert |
01/17/2024 | ADUS | Buy Now | Addus HomeCare | $94.54 | 24.81% | Oppenheimer | Michael Wiederhorn | → $118 | Reiterates | Outperform → Outperform | Get Alert |
12/12/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 11.06% | TD Cowen | Ryan Langston | → $105 | Initiates | → Outperform | Get Alert |
11/01/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 7.89% | RBC Capital | Ben Hendrix | $109 → $102 | Maintains | Outperform | Get Alert |
11/01/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 11.06% | Stephens & Co. | Scott Fidel | $110 → $105 | Maintains | Overweight | Get Alert |
08/02/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 24.81% | Oppenheimer | Michael Wiederhorn | → $118 | Reiterates | Outperform → Outperform | Get Alert |
08/02/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 11.06% | Raymond James | John Ransom | $100 → $105 | Maintains | Outperform | Get Alert |
08/02/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 16.35% | Stephens & Co. | Scott Fidel | $100 → $110 | Maintains | Overweight | Get Alert |
08/01/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 5.78% | Stephens & Co. | Scott Fidel | → $100 | Reiterates | Overweight → Overweight | Get Alert |
06/29/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 24.81% | Oppenheimer | Michael Wiederhorn | $118 → $118 | Reiterates | Outperform → Outperform | Get Alert |
05/26/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 24.81% | Oppenheimer | Michael Wiederhorn | → $118 | Reiterates | Outperform → Outperform | Get Alert |
05/05/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 5.78% | Raymond James | John Ransom | $125 → $100 | Maintains | Outperform | Get Alert |
05/03/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 15.3% | RBC Capital | Ben Hendrix | $123 → $109 | Maintains | Outperform | Get Alert |
05/03/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 24.81% | Oppenheimer | Michael Wiederhorn | $130 → $118 | Maintains | Outperform | Get Alert |
05/02/2023 | ADUS | Buy Now | Addus HomeCare | $94.54 | 30.1% | Stephens & Co. | Scott Fidel | → $123 | Reiterates | → Overweight | Get Alert |
The latest price target for Addus HomeCare (NASDAQ: ADUS) was reported by Barclays on April 23, 2024. The analyst firm set a price target for $83.00 expecting ADUS to fall to within 12 months (a possible -12.21% downside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for Addus HomeCare (NASDAQ: ADUS) was provided by Barclays, and Addus HomeCare downgraded their underweight rating.
There is no last upgrade for Addus HomeCare.
The last downgrade for Addus HomeCare Corp happened on April 23, 2024 when Barclays changed their price target from N/A to $83 for Addus HomeCare Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addus HomeCare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addus HomeCare was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
While ratings are subjective and will change, the latest Addus HomeCare (ADUS) rating was a downgraded with a price target of $0.00 to $83.00. The current price Addus HomeCare (ADUS) is trading at is $94.54, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.